HIMS wellness start-up all set to launch a new product line exclusive for women

1st November, Thursday, marked the 1 year anniversary of HIMS product line of men’s health products, and on that occasion, the San Francisco based company made an announcement of its foray into woman’s wellness.

In a bid to support its new brand called, HERS, the company said that it would make use of its mountain of venture capital.

As per reports, back in September, another $50 million was raised by HIMS in a round led by IVP.  According to a report published by PitchBook, the start-up was valued at $500 million to date at which it has raised $97 million.

“We have a goal of helping women make the most suitable choices about their health and wellness at every single stage of their journey”, states Hilary Coles, who leads the brand HERS in a recent interview.

As per reports, once it is launched, HERS would be offering three categories of products: hair loss treatments, skin care, and sexual wellness. In its line of sexual health products, it would be offering Addyi, the only FDA-approved medication for women with hypoactive sexual desire disorder and a prescription-based birth control pill.

For the skin, HERS would be offering a prescription topical cream to treat acne, a melasma corrector for hyperpigmentation, and an anti-aging cream. For hair products, HERS would be selling a hair, vitamin and skin supplement, shampoo and conditioner that protects against damaged hair that sheds.

As per reports, From January 2019, the company shall also begin selling women, Minoxidil, a treatment for hair thinning quite often prescribed to men. Excluding products like Addyi and birth control, they would range from $15 to $75 per month.

Founded in 2017, HIMS is backed by Redpoint Ventures, SV Angel, 8VC Forerunner Ventures, Founders Fund among many others. The San-Francisco company is also well-known for selling oral hygiene, skin care products and erectile dysfunction medication for men.

Leave A Reply

Your email address will not be published.